Cytokinetics Gains FDA Approval for MYQORZO in oHCM

Cytokinetics ( (CYTK) ) just unveiled an announcement.

On December 19, 2025, Cytokinetics announced that the U.S. Food and Drug Administration approved MYQORZO (aficamten) tablets in multiple strengths for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. MYQORZO, an allosteric and reversible inhibitor of cardiac myosin motor activity, works by reducing cardiac contractility and left ventricular outflow tract obstruction in oHCM patients, marking a significant commercial and clinical milestone that strengthens Cytokinetics’ position in the cardiovascular therapeutics market and expands treatment options for patients with this serious cardiac condition.

The most recent analyst rating on (CYTK) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Cytokinetics stock, see the CYTK Stock Forecast page.

Spark’s Take on CYTK Stock

According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.

Cytokinetics’ overall stock score is primarily impacted by its financial instability and challenging valuation. While technical indicators suggest neutral momentum, positive earnings call insights and corporate events provide some optimism. The company’s progress towards drug approvals and strategic leadership changes are notable positives, but financial challenges remain a significant concern.

To see Spark’s full report on CYTK stock, click here.

More about Cytokinetics

Cytokinetics is a biopharmaceutical company focused on developing small-molecule therapies that modulate cardiac muscle function, targeting serious cardiovascular diseases such as hypertrophic cardiomyopathy.

Average Trading Volume: 1,882,543

Technical Sentiment Signal: Buy

Current Market Cap: $7.31B

Find detailed analytics on CYTK stock on TipRanks’ Stock Analysis page.